Medicare Payments For Sensipar, Parsabiv Could Be Bellwether For Dialysis Drug Developers
Sensipar/Parsabiv marketer Amgen and three developers of new treatments for anemia emphasize importance to innovation of additional payments outside Medicare's reimbursement bundle for end-stage renal disease.
You may also be interested in...
Recent developments in US federal government regulation of prescription drug pricing and reimbursement.
Positive top-line data from the ALPS study confirms the efficacy and safety of roxadustat, a Phase III-stage product which could be the first a new class of orally active agents with potential in the treatment of anemia associated with chronic kidney disease.
More new dialysis drugs would be eligible for Medicare add-on payments under proposed rule, but payment amounts would be lower.